Most active investors · All time

Ranked by rounds participated in, from announcements across all periods. Lead counts include only confirmed lead roles.

Browse by month

8VCLatest Oct 22

Warhound · $200M Seed BigHat Biosciences · $75M Series C

5rounds

0led

Biotech 4Defense tech 1

Series A 2, Series C+ 2, Seed 1

Oct 22, 2026

Details

New companies 5 · Follow-on 0

Stages: Series A 2, Series C+ 2, Seed 1

Warhound $200M Seed BigHat Biosciences $75M Series C Latus Bio, Inc. $97M Series A

Breyer CapitalLatest Oct 22

Warhound · $200M Seed Soufflé Therapeutics · $135M Series B

5rounds

0led

Biotech 4Defense tech 1

Seed 2, Series B 1, Series C+ 1, Undisclosed 1

Oct 22, 2026

Details

New companies 5 · Follow-on 0

Stages: Seed 2, Series B 1, Series C+ 1, Undisclosed 1

Warhound $200M Seed Soufflé Therapeutics $135M Series B Network Bio $50M Strategic

Polaris PartnersLatest Oct 13

Soufflé Therapeutics · $135M Series B Tavo Biotherapeutics · $17M Series A

5rounds

0led

Biotech 5

Series B 3, Series A 1, Undisclosed 1

Oct 13, 2026

Details

New companies 5 · Follow-on 0

Stages: Series B 3, Series A 1, Undisclosed 1

Soufflé Therapeutics $135M Series B Tavo Biotherapeutics $17M Series A Crossbow Therapeutics $77M Series B

Illumina VenturesLatest Sep 18

Robigo · Undisclosed Series A Encoded Therapeutics Inc. · $275M Series F

5rounds

0led

Biotech 4Agritech 1

Series A 2, Series B 1, Series C+ 1, Undisclosed 1

Sep 18, 2026

Details

New companies 5 · Follow-on 0

Stages: Series A 2, Series B 1, Series C+ 1, Undisclosed 1

Robigo Undisclosed Series A Encoded Therapeutics Inc. $275M Series F Syntax Bio $14.4M Series A+

Gates FoundationLatest Aug 27

ProFound Therapeutics · $35M Strategic Leyden Laboratories · €40M Series B

5rounds

—led

Biotech 3Agritech 1AI 1

Undisclosed 3, Series A 1, Series B 1

Aug 27, 2026

Details

New companies 5 · Follow-on 0

Stages: Undisclosed 3, Series A 1, Series B 1

ProFound Therapeutics $35M Strategic Leyden Laboratories €40M Series B Kanvas Biosciences $48M Series A

Foresite CapitalLatest Aug 18

Abcuro · $66M Series D Khartis Therapeutics · $50M Series B

5rounds

—led

Biotech 5

Series A 2, Series C+ 2, Series B 1

Aug 18, 2026

Details

New companies 5 · Follow-on 0

Stages: Series A 2, Series C+ 2, Series B 1

Abcuro $66M Series D Khartis Therapeutics $50M Series B Slate Medicines $130M Series A

Samsara BioCapitalLatest Aug 18

Abcuro · $66M Series D Sidewinder Therapeutics · $137M Series B

5rounds

0led

Biotech 5

Series B 3, Series C+ 2

Aug 18, 2026

Details

New companies 5 · Follow-on 0

Stages: Series B 3, Series C+ 2

Abcuro $66M Series D Sidewinder Therapeutics $137M Series B Ambrosia Biosciences $100M Series B

TCGXLatest Aug 11

Vaderis Therapeutics · $152M Series B Ollin Biosciences · $330M Series B

5rounds

—led

Biotech 5

Series B 3, Series A 1, Series C+ 1

Aug 11, 2026

Details

New companies 5 · Follow-on 0

Stages: Series B 3, Series A 1, Series C+ 1

Vaderis Therapeutics $152M Series B Ollin Biosciences $330M Series B Adcendo $75M Series C

Frazier Life SciencesLatest Jul 22

Crystalys Therapeutics · $130M Series B RQ Bio · $115M Series A

5rounds

—led

Biotech 5

Series A 2, Series B 2, Series C+ 1

Jul 22, 2026

Details

New companies 5 · Follow-on 0

Stages: Series A 2, Series B 2, Series C+ 1

Crystalys Therapeutics $130M Series B RQ Bio $115M Series A Sidewinder Therapeutics $137M Series B

SR OneLatest Jul 22

Crystalys Therapeutics · $130M Series B Draig Therapeutics · $65M Series B

5rounds

—led

Biotech 4Healthtech 1

Series A 3, Series B 2

Jul 22, 2026

Details

New companies 4 · Follow-on 1

Stages: Series A 3, Series B 2

Crystalys Therapeutics $130M Series B Draig Therapeutics $65M Series B Poplar Therapeutics $45M Series A+

Johnson & Johnson Innovation – JJDCLatest Jun 23

TRIMTECH Therapeutics · $47M Seed+SonoThera · $125M Series B

5rounds

—led

Biotech 5

Series B 2, Undisclosed 2, Seed 1

Jun 23, 2026

Details

New companies 5 · Follow-on 0

Stages: Series B 2, Undisclosed 2, Seed 1

TRIMTECH Therapeutics $47M Seed+SonoThera $125M Series B TRex Bio $50M Undisclosed

Vivo CapitalLatest Jun 10

SonoThera · $125M Series B Full-Life Technologies · $150M Series D+Debt

5rounds

—led

Biotech 5

Series B 3, Undisclosed 2

Jun 10, 2026

Details

New companies 5 · Follow-on 0

Stages: Series B 3, Undisclosed 2

SonoThera $125M Series B Full-Life Technologies $150M Series D+Debt Oricell Therapeutics $110M Pre-IPO

LightspeedLatest Oct 22

Warp Sciences · $215M Series A Enveda · $311M Series E

4rounds

1led

Biotech 2Healthtech 2

Series C+ 2, Series A 1, Series B 1

Oct 22, 2026

Details

New companies 4 · Follow-on 0

Stages: Series C+ 2, Series A 1, Series B 1

Warp Sciences $215M Series A Enveda $311M Series E Triomics $22M Series B

Premji InvestLatest Oct 22

Warp Sciences · $215M Series A BigHat Biosciences · $75M Series C

4rounds

1led

Biotech 3Enterprise software 1

Series C+ 2, Seed 1, Series A 1

Oct 22, 2026

Details

New companies 4 · Follow-on 0

Stages: Series C+ 2, Seed 1, Series A 1

Warp Sciences $215M Series A BigHat Biosciences $75M Series C Enveda $311M Series E

4BIO CapitalLatest Oct 16

Estuary Biotherapeutics · $93M Series A Undecimal Bio · $18M Seed

4rounds

3led

Biotech 4

Seed 3, Series A 1

Oct 16, 2026

Details

New companies 4 · Follow-on 0

Stages: Seed 3, Series A 1

Estuary Biotherapeutics $93M Series A Undecimal Bio $18M Seed Aptadir Therapeutics €40M Seed

Jefferson Life SciencesLatest Oct 15

OMass Therapeutics · $310M Series C Draig Therapeutics · $65M Series B

4rounds

0led

Biotech 3Healthtech 1

Series B 2, Series A 1, Series C+ 1

Oct 15, 2026

Details

New companies 4 · Follow-on 0

Stages: Series B 2, Series A 1, Series C+ 1

OMass Therapeutics $310M Series C Draig Therapeutics $65M Series B FesariusTherapeutics $20M Series A

SV Health InvestorsLatest Oct 15

OMass Therapeutics · $310M Series C AdvanCell · $315M Series D

4rounds

0led

Biotech 4

Series C+ 2, Series B 1, Undisclosed 1

Oct 15, 2026

Details

New companies 4 · Follow-on 0

Stages: Series C+ 2, Series B 1, Undisclosed 1

OMass Therapeutics $310M Series C AdvanCell $315M Series D Draig Therapeutics $65M Series B

IndustrifondenLatest Oct 14

OlsAro · €5M Seed AnaCardio · €62.5M Series B

4rounds

1led

Biotech 3Agritech 1

Series B 2, Seed 1, Undisclosed 1

Oct 14, 2026

Details

New companies 4 · Follow-on 0

Stages: Series B 2, Seed 1, Undisclosed 1

OlsAro €5M Seed AnaCardio €62.5M Series B EnginZyme SEK 75M Equity round

Leaps by BayerLatest Oct 13

Soufflé Therapeutics · $135M Series B Robigo · Undisclosed Series A

4rounds

1led

Biotech 3Agritech 1

Series B 2, Growth 1, Series A 1

Oct 13, 2026

Details

New companies 4 · Follow-on 0

Stages: Series B 2, Growth 1, Series A 1

Soufflé Therapeutics $135M Series B Robigo Undisclosed Series A Celea Therapeutics $180M Growth

Saras CapitalLatest Oct 13

Undecimal Bio · $18M Seed Shennon Biotechnologies · $12M Funding

4rounds

0led

Biotech 2Agritech 1AI 1

Undisclosed 2, Seed 1, Series A 1

Oct 13, 2026

Details

New companies 4 · Follow-on 0

Stages: Undisclosed 2, Seed 1, Series A 1

Undecimal Bio $18M Seed Shennon Biotechnologies $12M Funding Converge Bio $25M Series A

Mission BioCapitalLatest Sep 29

Breye Therapeutics · €67.5M Series A Cloverleaf Bio · $33M Seed

4rounds

1led

Biotech 4

Seed 2, Series A 1, Series B 1

Sep 29, 2026

Details

New companies 4 · Follow-on 0

Stages: Seed 2, Series A 1, Series B 1

Breye Therapeutics €67.5M Series A Cloverleaf Bio $33M Seed Enodia Therapeutics €20.7M Seed

Modi VenturesLatest Sep 29

Breye Therapeutics · €67.5M Series A Latus Bio, Inc. · $97M Series A

4rounds

0led

Biotech 4

Series A 2, Series B 1, Undisclosed 1

Sep 29, 2026

Details

New companies 4 · Follow-on 0

Stages: Series A 2, Series B 1, Undisclosed 1

Breye Therapeutics €67.5M Series A Latus Bio, Inc. $97M Series A Exciva €51M Series B

Baillie GiffordLatest Sep 23

Enveda · $311M Series E Chai Discovery · $400M Series C

4rounds

0led

Biotech 4

Series C+ 4

Sep 23, 2026

Details

New companies 4 · Follow-on 0

Stages: Series C+ 4

Enveda $311M Series E Chai Discovery $400M Series C Loyal $100M Series C

DimensionLatest Sep 23

Enveda · $311M Series E Chai Discovery · $400M Series C

4rounds

0led

Biotech 3Industrial tech 1

Series C+ 3, Series B 1

Sep 23, 2026

Details

New companies 4 · Follow-on 0

Stages: Series C+ 3, Series B 1

Enveda $311M Series E Chai Discovery $400M Series C Congruence Therapeutics $39.5M Series B

T. Rowe Price Investment ManagementLatest Sep 23

Enveda · $311M Series E Ollin Biosciences · $330M Series B

4rounds

0led

Biotech 4

Series B 2, Series C+ 2

Sep 23, 2026

Details

New companies 4 · Follow-on 0

Stages: Series B 2, Series C+ 2

Enveda $311M Series E Ollin Biosciences $330M Series B Cellares $257M Series D

True VenturesLatest Sep 23

Basecamp Research · $140M Series C Enveda · $311M Series E

4rounds

0led

Biotech 4

Seed 2, Series C+ 2

Sep 23, 2026

Details

New companies 4 · Follow-on 0

Stages: Seed 2, Series C+ 2

Basecamp Research $140M Series C Enveda $311M Series E Patina $2M Seed

NoshaqLatest Sep 21

Novadip Biosciences · €10.4M Convertible financing Amyl Therapeutics · €8.3M Series A extension

4rounds

0led

Biotech 3Foodtech 1

Series A 2, Series B 1, Undisclosed 1

Sep 21, 2026

Details

New companies 4 · Follow-on 0

Stages: Series A 2, Series B 1, Undisclosed 1

Novadip Biosciences €10.4M Convertible financing Amyl Therapeutics €8.3M Series A extension Brenus Pharma €11M Series A

YK BioventuresLatest Sep 18

Tempo Therapeutics · $14.5M Funding Moonwalk Biosciences · $70M Series B

4rounds

1led

Biotech 4

Series A 2, Series B 1, Undisclosed 1

Sep 18, 2026

Details

New companies 4 · Follow-on 0

Stages: Series A 2, Series B 1, Undisclosed 1

Tempo Therapeutics $14.5M Funding Moonwalk Biosciences $70M Series B Think Bioscience $55M Series A

Insight PartnersLatest Sep 9

TwoStep Therapeutics · $62.5M Series A Superluminal Medicines · $60M Series B

4rounds

0led

Biotech 3Healthtech 1

Series A 2, Series B 1, Series C+ 1

Sep 9, 2026

Details

New companies 4 · Follow-on 0

Stages: Series A 2, Series B 1, Series C+ 1

TwoStep Therapeutics $62.5M Series A Superluminal Medicines $60M Series B Iterative Health $77M Series C

Draper AssociatesLatest Sep 8

Cloverleaf Bio · $33M Seed Syntax Bio · $14.4M Series A+

4rounds

0led

Biotech 2AI 1Industrial tech 1

Series A 2, Seed 1, Undisclosed 1

Sep 8, 2026

Details

New companies 4 · Follow-on 0

Stages: Series A 2, Seed 1, Undisclosed 1

Cloverleaf Bio $33M Seed Syntax Bio $14.4M Series A+Apoha Undisclosed Series A

“—” in Led means every role for that investor in this period is undisclosed; it does not mean zero leads. New companies counts the first participation in a company in our records; follow-on counts later participation.